'Multiple morbidities' greatest NICE challenge
This article was originally published in Scrip
Executive Summary
NICE chair Professor David Haslam told a packed gathering at the FT's global pharmaceutical and biotechnology conference on 3 December that since joining the organization six months ago, his two greatest challenges have been "tackling multiple morbidities" and "implementation."